The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Treatment Options, Guidelines for Managing Gout Discussed at the ACR/ARHP Winter Rheumatology Symposium

Treatment Options, Guidelines for Managing Gout Discussed at the ACR/ARHP Winter Rheumatology Symposium

April 2, 2014 • By Kimberly Retzlaff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium
  • ACR Releases Guidelines for Gout Management
  • Treatment, Management Options for Difficult-to-Control Gout
Explore This Issue
April 2014
Also By This Author
  • How to Document E/M Services
ACR's Gout Guidelines
The base of the big toe and ankle are red, swollen, and extremely painful due to an acute attack of gout.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The incidence of gout has been steadily increasing during the past few decades, from about 0.5% of the population in the early 1970s to about 4% as of 2010, making it increasingly important to provide quality care to this patient population. To improve the quality of gout care, both physicians and patients need to understand the goals and effects of gout therapy, said Michael H. Pillinger, MD, associate professor of medicine and biochemistry and molecular pharmacology, NYU School of Medicine, New York, at the ACR’s Winter Rheumatology Symposium this January in Snowmass, Colo. During the session, Update on Gout Therapy: The ACR 2012 Treatment Guidelines and Beyond, Dr. Pillinger discussed current treatment options and the recently published ACR guidelines.

Quality of Care

Overall, the quality of gout care today is poor, Dr. Pillinger said. “A very big underlying reason [for this] is a lack of understanding on the [part] of both patients and physicians about the nature of the disease. Managing attacks is the tip of the iceberg,” he explained. Although the pain from a gout attack can be treated with nonsteroidal antiinflammatory drugs (NSAIDs), failing to manage gout effectively tends to make the gout worse over time and increases the frequency of attacks.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Another complication is that the consequence of treating gout properly is that it will actually make the patient worse for a period of time, Dr. Pillinger said. If the patient is not treated with antiinflammatory medication in addition to urate-lowering therapy during the “vulnerable window,” which can last 6–24 months or longer, the patient is likely to blame the gout medication for increased attacks and stop taking it.

It’s also important to “treat to target,” Dr. Pillinger said. It’s not enough to put the patient on urate-lowering therapy; follow-up is needed to ensure the patient is progressing toward an appropriate urate level. The keys to quality treatment are “understanding and knowing the nature of the targets, and recognizing that gout is a long-term disease not a short-term disease,” Dr. Pillinger said. “One of the main goals of the ACR treatment guidelines is to lay this out for practitioners, and they’re valuable in that regard.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
This image shows the chemical structure of a uric acid molecule.
This image shows the chemical structure of a uric acid molecule.

ACR Gout Treatment Guidelines

The 2012 American College of Rheumatology Guidelines for Management of Gout were published after a process of literature review and appraisal. During the review process, core expert panels (CEPs) and task force panels (TFPs) convened to investigate four areas of interest: therapy of acute gouty arthritis, urate lowering, antiinflammatory prophylaxis and management of chronic tophaceous gouty arthropathy. To determine whether each recommendation would be included in the guidelines, the panel members assigned ratings independently, then shared the ratings, discussed and voted. Recommendations that are included in the guidelines also include quality ratings to indicate the level of evidence that supports the practice.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Crystal Arthritis, Meeting Reports Tagged With: antiinflammatory, crystal arthritis, Gout, patient care, rheumatologist, rheumatology symposium, TreatmentIssue: April 2014

You Might Also Like:
  • Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium
  • ACR Releases Guidelines for Gout Management
  • Treatment, Management Options for Difficult-to-Control Gout
  • Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.